New insight into genetic schizophrenia risk
A genetic change increases the risk of developing schizophrenia and highlights new opportunities for drug treatment, according to a study involving the University of Strathclyde.
In the human genome, small sections of DNA have been found to be duplicated (copied) or deleted in a small number of people, in a phenomenon known as Copy Number Variation.
Some of these genetic changes are linked to an increased risk of developing neurodevelopmental disorders, such as schizophrenia and autism, but the disease mechanisms involved remain largely unknown.
For example, people with a DNA duplication at chromosome 16p11.2, which results in having extra copies of around 30 different genes, are approximately 15 times more likely to develop schizophrenia than people without the duplication. Why this should be the case is very poorly understood.
For the first time, research reported by the team in the journal Cell Reports, has shown that the 16p11.2 duplication impacts on a number of different inhibitory neuron types, neurons that use the neurotransmitter GABA, in brain areas dysfunctional in schizophrenia. These brain areas include the prefrontal cortex, hippocampus and amygdala.
The researchers also show that these GABA neuron changes are accompanied by impaired functional communication between the same brain regions. Importantly, the researchers found that 16p11.2 duplication also results in cognitive and social deficits. These deficits not only parallel those seen in patients with schizophrenia, but are also known to involve the brain regions identified as being dysfunctional as a result of 16p11.2 duplication.
Judith Pratt, Research Professor with Strathclyde Institute of Pharmacy and Biomedical Sciences and a partner in the study, highlighted the potential opportunity for drug development offered by the findings.
She said: “The current drug treatment options available for people with schizophrenia are limited, only effective for some patients and often involve severe side effects. Drugs to help patients with their cognitive and social problems are particularly urgently needed, as these symptoms dramatically impact on their quality of life.
“Our findings highlight the potential of drugs targeting the GABA neurons and provide a range of translational biomarker measures against which we can test the potential therapeutic efficacy of these and other drugs for schizophrenia”.
The collaborative research also involved the Universities of Lancaster and Glasgow. It was funded by the Medical Research Council.